Fly News Breaks for March 4, 2020
Mar 4, 2020 | 17:04 EDT
Citi analyst Joanne Wuensch initiated coverage of NuVasive with a Neutral rating and $68 price target. The analyst is positive on the company's leadership position in a fragmented market for spine surgery with currently under-appreciated X360 asset, but also sees its valuation on enterprise value to expected FY21 revenue basis as in line with its 5-year average.
News For NUVA From the Last 2 Days
There are no results for your query NUVA